dc.contributor.author | Ramírez, Laura | |
dc.contributor.author | Iborra, Salvador | |
dc.contributor.author | Cortés, Jimena | |
dc.contributor.author | Bonay, Pedro | |
dc.contributor.author | Alonso, Carlos | |
dc.contributor.author | Barral-Netto, Manoel | |
dc.contributor.author | Soto, Manuel | |
dc.date.accessioned | 2019-02-19T09:52:57Z | |
dc.date.available | 2019-02-19T09:52:57Z | |
dc.date.issued | 2010-06 | |
dc.identifier.citation | J Biomed Biotechnol. 2010;2010:181690. | es_ES |
dc.identifier.issn | 1110-7243 | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/7179 | |
dc.description.abstract | Leishmaniasis is an increasing public health problem and effective vaccines are not currently available. We have previously demonstrated that vaccination with ribosomal proteins extracts administered in combination of CpG oligodeoxynucleotides protects susceptible BALB/c mice against primary Leishmania major infection. Here, we evaluate the long-term immunity to secondary infection conferred by this vaccine. We show that vaccinated and infected BALB/c mice were able to control a secondary Leishmania major challenge, since no inflammation and very low number of parasites were observed in the site of reinfection. In addition, although an increment in the parasite burden was observed in the draining lymph nodes of the primary site of infection we did not detected inflammatory lesions at that site. Resistance against reinfection correlated to a predominant Th1 response against parasite antigens. Thus, cell cultures established from spleens and the draining lymph node of the secondary site of infection produced high levels of parasite specific IFN-gamma in the absence of IL-4 and IL-10 cytokine production. In addition, reinfected mice showed a high IgG2a/IgG1 ratio for anti-Leishmania antibodies. Our results suggest that ribosomal vaccine, which prevents pathology in a primary challenge, in combination with parasite persistence might be effective for long-term maintenance of immunity. | es_ES |
dc.description.sponsorship | This study was supported by the Ministerio de Ciencia e Innovación and the Instituto de Salud Carlos III within the Network of Tropical Diseases Research (RICET RD06/0021/0008). Grants from Ministerio de Ciencia e Innovación (FIS/PI080101), from AECID (A/016407/08), from CYTED (207RT0308) and a Grant from Laboratorios LETI S.L. are acknowledged. An institutional grant from Fundación Ramón Areces is also acknowledged. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Hindawi | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject.mesh | Animals | es_ES |
dc.subject.mesh | Antigens, Protozoan | es_ES |
dc.subject.mesh | Cytokines | es_ES |
dc.subject.mesh | Disease Models, Animal | es_ES |
dc.subject.mesh | Female | es_ES |
dc.subject.mesh | Leishmania major | es_ES |
dc.subject.mesh | Leishmaniasis Vaccines | es_ES |
dc.subject.mesh | Leishmaniasis, Cutaneous | es_ES |
dc.subject.mesh | Mice | es_ES |
dc.subject.mesh | Mice, Inbred BALB C | es_ES |
dc.subject.mesh | Oligodeoxyribonucleotides | es_ES |
dc.subject.mesh | Protozoan Proteins | es_ES |
dc.subject.mesh | Ribosomal Proteins | es_ES |
dc.subject.mesh | CPG-oligonucleotide | es_ES |
dc.title | BALB/c Mice Vaccinated withLeishmania majorRibosomal Proteins Extracts Combined with CpG Oligodeoxynucleotides Become Resistant to Disease Caused by a Secondary Parasite Challenge | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución-4.0 Internacional | * |
dc.identifier.pubmedID | 20145701 | es_ES |
dc.format.volume | 2010 | es_ES |
dc.format.page | 9 | es_ES |
dc.identifier.doi | 10.1155/2010/181690 | es_ES |
dc.contributor.funder | Ministerio de Ciencia e Innovación (España) | |
dc.contributor.funder | Instituto de Salud Carlos III | |
dc.contributor.funder | Agencia Española de Cooperación Internacional para el Desarrollo | |
dc.contributor.funder | Programa Iberoamericano de Ciencia y Tecnología para el Desarrollo (España) | |
dc.contributor.funder | Laboratorios LETI | |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1110-7251 | es_ES |
dc.relation.publisherversion | https://www.doi.org/10.1155/2010/181690 | es_ES |
dc.identifier.journal | Journal of Biomedicine and Biotechnology | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/RD06/0021/0008 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/PI080101 | es_ES |
dc.rights.accessRights | open access | es_ES |